当前位置：
X-MOL 学术
›
Ther. Adv. Med. Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Proteomic analysis of gemcitabine-resistant pancreatic cancer cells reveals that microtubule-associated protein 2 upregulation associates with taxane treatment
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-05-10 , DOI: 10.1177/1758835919841233 Tessa Ya Sung Le Large 1 , Btissame El Hassouni 2 , Niccola Funel 3 , Bart Kok 4 , Sander R Piersma 2 , Thang V Pham 2 , Kenneth P Olive 5 , Geert Kazemier 4 , Hanneke W M van Laarhoven 6 , Connie R Jimenez 2 , Maarten F Bijlsma 7 , Elisa Giovannetti 8
Therapeutic Advances in Medical Oncology ( IF 4.3 ) Pub Date : 2019-05-10 , DOI: 10.1177/1758835919841233 Tessa Ya Sung Le Large 1 , Btissame El Hassouni 2 , Niccola Funel 3 , Bart Kok 4 , Sander R Piersma 2 , Thang V Pham 2 , Kenneth P Olive 5 , Geert Kazemier 4 , Hanneke W M van Laarhoven 6 , Connie R Jimenez 2 , Maarten F Bijlsma 7 , Elisa Giovannetti 8
Affiliation
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a high lethality, with only 7% of patients alive 5 years after diagnosis.1 Most patients present with advanced disease stages, either locally advanced (stage III) or with distant metastases (stage IV), leaving palliative chemotherapy as the only therapeutic option.2 Aggressive multimodal therapy offers the best survival chances for patients diagnosed with early stage disease (stage I–IIb).3 This treatment consists of a combination of resection followed by adjuvant chemotherapy. Currently, standard adjuvant therapy consists of six cycles of gemcitabine improving disease-free survival (DFS) from 6.7 to 13.4 months.3,4
中文翻译：
吉西他滨耐药胰腺癌细胞的蛋白质组学分析表明，微管相关蛋白 2 上调与紫杉烷治疗相关
胰腺导管腺癌 (PDAC) 的特点是致死率高，诊断后 5 年只有 7% 的患者存活。1大多数患者出现疾病晚期，局部晚期（III 期）或远处转移（IV 期），姑息性化疗是唯一的治疗选择。2积极的多模式治疗为诊断为早期疾病（I-IIb 期）的患者提供最佳生存机会。3这种治疗包括切除和辅助化疗的组合。目前，标准辅助治疗包括六个周期的吉西他滨，将无病生存期 (DFS) 从 6.7 个月提高到 13.4 个月。3,4
更新日期：2019-05-10
中文翻译：
吉西他滨耐药胰腺癌细胞的蛋白质组学分析表明，微管相关蛋白 2 上调与紫杉烷治疗相关
胰腺导管腺癌 (PDAC) 的特点是致死率高，诊断后 5 年只有 7% 的患者存活。1大多数患者出现疾病晚期，局部晚期（III 期）或远处转移（IV 期），姑息性化疗是唯一的治疗选择。2积极的多模式治疗为诊断为早期疾病（I-IIb 期）的患者提供最佳生存机会。3这种治疗包括切除和辅助化疗的组合。目前，标准辅助治疗包括六个周期的吉西他滨，将无病生存期 (DFS) 从 6.7 个月提高到 13.4 个月。3,4
京公网安备 11010802027423号